Perrigo to release Q2 2026 financial results on August 5

1 min read     Updated on 22 Jul 2026, 08:19 PM
scanx
Reviewed by
Ashish TScanX News Team
AI Summary

Perrigo Company plc will release its second quarter 2026 financial results on Wednesday, August 5, 2026. A conference call hosted by Interim President and CEO Albert Manzone and CFO Eduardo Bezerra will follow at 8:30 a.m. EST. The call will be available via webcast and phone, with a replay accessible until August 12, 2026.

powered bylight_fuzz_icon
46277374

*this image is generated using AI for illustrative purposes only.

Perrigo Company plc will release its second quarter 2026 financial results on Wednesday, August 5, 2026. The company will hold a conference call beginning at 8:30 a.m. EST to discuss the performance, hosted by Interim President and CEO Albert Manzone and CFO Eduardo Bezerra.

Conference Call Details

The earnings call will be accessible live via webcast through the investor relations section of the Perrigo website. Participants may also join by phone using the following numbers and conference ID:

Region Phone Number Conference ID
U.S. 800-836-8184 98476
International 646-357-8785 98476

A replay of the call will be available beginning at approximately 12:00 p.m. EST on August 5, 2026, through Wednesday, August 12, 2026. To access the replay, dial 888-660-6345 (U.S.) or 646-517-4150 (International) and enter access code 98476 #.

About Perrigo Company plc

Perrigo Company plc is a leading pure-play self-care company with over a century of experience in providing high-quality health and wellness solutions to consumers primarily in North America and Europe. The company operates as a pioneer in the over-the-counter (OTC) self-care market, offering trusted solutions that do not require a prescription. Perrigo's business model leverages cash-generative store brand private label offerings to fuel investments for leading brands, including Opill®, Mederma®, Compeed®, EllaOne®, and Jungle Formula®.

How will Perrigo's Q2 2026 financial results reflect the performance of its key brands like Opill® and Mederma®?

What strategic initiatives might Interim CEO Albert Manzone highlight during the call to drive future growth?

How is Perrigo positioning itself to capitalize on trends in the self-care and OTC markets in North America and Europe?

like18
dislike

Perrigo appoints Albert A. Manzone interim CEO, reaffirms FY26 guidance

1 min read     Updated on 09 Jun 2026, 03:32 AM
scanx
Reviewed by
Riya DScanX News Team
AI Summary

Perrigo Company plc appointed Albert A. Manzone as Interim President and CEO, succeeding Patrick Lockwood-Taylor, who resigned immediately. The Board has begun a search for a permanent successor. Perrigo reaffirmed its FY26 guidance, including All In net sales growth of (5.5)% to (1.5)% and All In adjusted EPS of $2.00 to $2.30.

powered bylight_fuzz_icon
42501699

*this image is generated using AI for illustrative purposes only.

Perrigo Company plc has appointed Albert A. Manzone as Interim President and Chief Executive Officer, effective immediately, following the resignation of Patrick Lockwood-Taylor. The leadership change impacts the company's executive structure while the Board of Directors initiates a comprehensive search process to identify a permanent successor. Perrigo also reaffirmed its financial guidance for the full year 2026, providing stability to investors amid the transition.

Leadership Transition

Albert A. Manzone, a member of the Perrigo Board, assumes the role of Interim President and CEO immediately. He succeeds Patrick Lockwood-Taylor, who has resigned as President, CEO, and as a member of the Board, effective immediately. The Board has commenced a search for a permanent replacement to lead the provider of Consumer Self-Care Products.

FY26 Financial Outlook

Perrigo confirmed its full-year 2026 outlook, which was initially provided in its first quarter 2026 earnings press release issued on May 6, 2026. The guidance covers both All In and Core financial metrics.

Metric FY26 Guidance
All In net sales growth (5.5)% to (1.5)%
All In adjusted EPS $2.00 to $2.30
Core net sales growth (3.0)% to +1.0%
Core adjusted EPS $2.25 to $2.55

The reaffirmation signals management's confidence in the company's performance trajectory for the remainder of the fiscal year.

What criteria will the Board prioritize when selecting a permanent CEO to drive Perrigo's long-term growth?

How might the leadership transition affect Perrigo's strategic initiatives in the Consumer Self-Care Products market?

Will the interim leadership pursue any operational changes or cost-cutting measures to meet the FY26 guidance?

like15
dislike